Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Summing up 100 years of asthma.
TL;DR: The recognition of its heterogeneous nature in combination with several refined and sophisticated technologies will mark a new era of phenotype-specific approach and treatment of asthma.
Journal ArticleDOI
Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy.
TL;DR: It is suggested that anti-IgE mAb might improve the safety, rapidity, and efficacy of OIT, which can reduce allergic reactions associated with food administration.
Journal ArticleDOI
The Use of Rasch Analysis in Reducing a Large Condition-Specific Instrument for Preference Valuation: The Case of Moving from AQLQ to AQL-5D
TL;DR: Rasch analysis proved to be a useful tool in assisting in the initial process of selecting items from an existing health-related quality-of-life instrument in the construction of the AQL-5D, the first stage in developing a condition-specific preference-based measure for asthma patients.
Journal ArticleDOI
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
Stephanie Korn,Christian Schumann,Cornelia Kropf,Kathrin M. Stoiber,A. Thielen,Christian Taube,Roland Buhl +6 more
TL;DR: The present study confirms the clinical efficacy of omalizumab in patients with severe allergic asthma irrespective of age in a real-life setting outside the omalIZumab trial program.
Journal ArticleDOI
An algorithmic approach for the treatment of severe uncontrolled asthma
Eleftherios Zervas,Konstantinos Samitas,Andriana I. Papaioannou,Petros Bakakos,Stelios Loukides,Mina Gaga +5 more
TL;DR: A definition for severe asthma is reviewed, all therapeutic options currently available for these severe asthma patients are presented and a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma is suggested based on specific phenotype characteristics and biomarkers.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.